TinyGemsBreaks Archive - Page 84 of 126

TuesdayJan 10, 2023 11:47 am

TinyGemsBreaks – QSAM Biosciences Inc. (QSAM) Releases Shareholder Letter Outlining 2022 Updates, 2023 Milestone Goals

QSAM Biosciences (OTCQB: QSAM), a company developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP, or CycloSam(R), for the treatment of bone cancer and related diseases, has provided key updates and milestone goals in a shareholder letter; the letter is from QSAM Biosciences executive chair and cofounder C. Richard Piazza and CEO and cofounder Douglas Baum. The letter noted that QSAM is developing its lead therapeutic radiopharmaceutical drug candidate, CycloSam, to treat cancer that has either originated in the bone or has metastasized to the bone from the breast, prostate, lung or other organs. During 2022, CycloSam received rare pediatric disease designation for the…

TuesdayJan 10, 2023 11:35 am

TinyGemsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Key Milestones, 2023 Business Outlook

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, today outlined key accomplishments from 2022 and provided a business update and catalysts for 2023. “Over the course of 2022, we strengthened our position as a leader in rare cannabinoid R&D, creating a unique offering as the only company that has the breadth and depth in cannabinoid drug research, development and significant manufacturing know-how,” said Eric A. Adams, InMed president and CEO. “Despite the many economic pressures affecting businesses on a global scale, including challenging capital markets, particularly in biotech, InMed…

MondayJan 09, 2023 2:13 pm

TinyGemsBreaks – Knightscope, Inc. (NASDAQ: KSCP) Kicks Off New Year with Multiple New Contracts, Announces Planned Path to Profitability

Knightscope (NASDAQ: KSCP), a developer of advanced physical security technologies focused on enhancing U.S. security operations, announced that it has secured four new contracts in a successful start of 2023. Under the contracts, Knightscope will deploy three K5 Autonomous Security Robots (“ASRs”) and five K1 Blue Light Towers. The deployment locations include an existing Knightscope channel partner’s regional corporate office in Jacksonville, Florida, an Illinois-based casino, as well as the parking lot of an apartment complex for a well-known learning institution. A teaching hospital has also purchased five K1 Blue Light Towers to improve communications and safety on its New…

MondayJan 09, 2023 1:10 pm

TinyGemsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Leveraging Colombia, US Facilities to Distinguish Itself Within Highly Competitive Space

Flora Growth Corp. (NASDAQ: FLGC), a cannabis cultivator and global distributor, is a rapidly growing house of brands building customer bases and distribution channels across international lines as it aims to distinguish itself within a highly competitive arena. “Much of Flora Growth’s strength lies in its licensed cultivation, extraction and isolation facility located in northern Colombia’s fertile climate, where an experienced labor force is helping the nation emerge from decades of drug war illicit trade into a recognized and regulated market,” a recent article reads. “From its 247 acres of growing fields, the company’s harvests move into a production pipeline…

MondayJan 09, 2023 12:19 pm

TinyGemsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Berubicin Poised to Potentially Change History

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical innovator, is enrolling patients in the United States and Europe for its potentially pivotal global clinical trial in humans for its lead drug candidate designed to treat glioblastoma multiforme (“GBM”), a common and one of the most aggressive primary brain cancers. “The drug, Berubicin, is an anthracycline chemotherapy agent that apparently has the unique ability to cross the blood-brain barrier to target tumors directly. The inability of anthracyclines to cross the blood-brain barrier has been identified as a major obstacle in treating aggressive brain tumors such as GBM and creates an opportunity for CNS…

MondayJan 09, 2023 10:26 am

TinyGemsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Releases Status Update on Clinical Development Programs

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), is discussing upcoming priorities and near-term milestones regarding the status of its two clinical programs aimed at addressing multiple mental health conditions: CYB003 and CYB004. Designed for the treatment of Major Depressive Disorder (“MDD”), CYB003 is currently in a phase 1/2a clinical trial. CYB003 is a deuterated psilocybin analog. CYBN anticipates releasing an interim readout from the trial by the end of February 2023, which will provide an initial understanding of the safety and pharmacokinetic (“PK”) profile of the substance in humans. This interim data will…

FridayJan 06, 2023 1:00 pm

TinyGemsBreaks – Freight Technologies Inc. (NASDAQ: FRGT) Releases Projections for Double-Digit Revenue Growth in 2023

Freight Technologies (NASDAQ: FRGT), a technology company developing solutions to optimize and automate the supply chain process and providing its Fr8App platform for business-to-business, cross-border shipping in the USMCA region, has announced its 2023 guidance for revenue. According to the announcement, the company anticipates revenue this year to reach somewhere between $36 to $42 million; the company reported 2022 revenue of approximately $26 to $27 million. “We look forward to continued growth in our cross-border and domestic FTL offerings over the course of the next 12 to 24 months and come into 2023 with a strong pipeline of existing customers…

FridayJan 06, 2023 11:14 am

TinyGemsBreaks – Cepton Inc.’s (NASDAQ: CPTN) Vista-X120 Plus Featured in FreightWaves Article

Cepton (NASDAQ: CPTN), a Silicon Valley innovator of high-performance lidar solutions, was featured in a recent article published by FreightWaves. The piece, written by Jack Daleo and titled “Cepton unveils slimmed-down lidar solution,” discusses the Vista-X120 Plus, which offers easy integration at a height of 30 mm. “As the autonomous vehicle industry begins to gather steam, manufacturers of lidar — short for light detection and ranging — are trying to do more with less. Cepton (NASDAQ: CPTN), one of the few publicly traded lidar companies in the U.S., on Tuesday unveiled the Vista-X120 Plus, billed as ‘the world’s slimmest software…

ThursdayJan 05, 2023 1:15 pm

TinyGemsBreaks – Freight Technologies Inc. (NASDAQ: FRGT) Secures Stream of Steady Business on Fr8App Platform

Freight Technologies (NASDAQ: FRGT) (“Fr8Tech”), a company specializing in creating and providing supply chain optimization and automation solutions, and Freight App Inc. (“Fr8App”), its wholly owned subsidiary, have always sought to create offerings that contribute to their clients’ success by improving efficiency and profitability. “Designed to help solve shippers’ needs to secure freight capacity over time rather than on a trip-by-trip basis and guarantee carriers a steady stream of revenue, Fr8PrivateFleet matches carriers with the capacity for predetermined amount of load over a stated period with shippers… The advantages of Fr8PrivateFleet persuaded new and existing Fr8App customers to integrate it…

ThursdayJan 05, 2023 12:32 pm

TinyGemsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO to Present at Virtual Investor 2023 ‘Companies to Watch’

CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system. The company today announced that its Chief Executive Officer John Climaco will present at the Virtual Investor 2023 “Companies to Watch” event. Climaco’s presentation is scheduled to take place beginning at 10 a.m. ET on Wednesday, Jan. 18, 2023. A live video webcast of the presentation will be available on the Events page of CNS Pharmaceuticals’ website, and a replay will be available two hours following the live presentation and accessible for 90…

Spotlighting undiscovered companies with enormous upside potential.

Contact us: (512) 354-7000

TinyGemsBreaks